Thymosin alpha-1 monograph

Thymosin alpha-1

Overview

Thymosin alpha-1 is a synthetic 28-amino-acid peptide and immune modulator derived from the thymic hormone thymosin fraction 5. It has been studied mainly for chronic viral hepatitis and other immune-dysregulation states, but it is not a bodybuilding drug with established performance benefits. Human evidence is strongest for immunologic effects and selected infectious-disease indications, while sports-use claims are largely extrapolation or anecdote.

Pharmacokinetics & Mechanism

• Class: Synthetic thymic peptide immunomodulator
• Mechanism of action: Thymosin alpha-1 is thought to augment and regulate cell-mediated immunity, especially T-cell function and thymocyte differentiation. Reviews describe it as a peptidic biological response modifier that can increase the number and function of T cells; exact receptor-level pharmacology is not well established in routine clinical sources. Its practical effect is immunomodulatory rather than anabolic.
• Target(s): Immune-system pathways rather than a single validated receptor target. Reported effects include enhanced T-cell differentiation/maturation, improved antigen presentation, increased Th1-type cytokine signaling, and reduced T-cell apoptosis. A precise human receptor target is not well established.
• Route(s) of administration: Subcutaneous injection is the standard route in human clinical studies and review dosing. The drug is also reported as injectable in medical use; oral bioavailability is not established and is not the standard route.
• Onset: Not well established for subjective performance effects. In human pharmacokinetic data, serum levels peak within about 2 hours after subcutaneous dosing, with blood levels returning toward baseline within 24 hours.
• Half-life: Approximately 2 hours in the 2001 review of human pharmacology; another common practical takeaway is that serum levels return to baseline within 24 hours. I did not find a stronger modern human PK source here that clearly contradicts that estimate, but published PK data are limited.
• Metabolism / clearance: Not well established in detail in public human sources. As a peptide, it is expected to undergo proteolytic degradation and clearance like other small peptides, but the exact metabolic pathways and organ-specific clearance are not clearly established in the sources reviewed.